In a breakthrough discovery, a team of researchers from Columbia University and University Hospital Tubingen has identified a key molecular switch responsible for the exhaustion of CAR T-cells in the fight against solid tumors. The transcription factor NFIL3, which acts as a master regulator of gene activity, was found to drive T-cell exhaustion, the process that leads engineered cancer-killing cells to become dormant before completing their mission. Michel Sadelain and Judith Feucht led the research, focusing on the mechanism behind CAR T-cell therapy’s known weakness against solid tumors.
By employing CRISPR gene editing, they successfully deleted the gene that produces NFIL3 in modified CAR T cells, resulting in cells that remained active, multiplied, and continued to attack. In mouse models of solid tumors, the edited cells demonstrated improved tumor control, extending survival times.
This finding holds significant importance as solid tumors, including breast, lung, and pancreatic cancers, account for the majority of human cancers. While current CAR T therapies exhibit success in treating certain blood cancers, they have struggled against solid masses. The research, published in the journal Cancer Discovery, marks an essential step forward.
Although no patient has yet received these edited cells and no clinical trial has commenced, the logic of the approach fills researchers with optimism. By targeting the biology of exhaustion rather than a specific tumor type, they believe the impact could be wide-ranging.
If the switch functions similarly across various cancers, the potential for a broad application of the fix follows. The team meticulously screened several transcription factors before zeroing in on NFIL3, the primary driver of exhaustion. The identification of this key driver serves as the core of the discovery, opening the door for further research and potential treatment options.
CRISPR made the edit possible, allowing the researchers to delete the NFIL3 gene with precision, resulting in a CAR T cell that no longer tires. Instead, it continued to produce and attack.
While there are caveats, such as the differences between mouse models and humans, the immune systems, and the tumors, the timeline from lab to clinic is long, and many promising discoveries never become treatments, the finding still represents a significant stride. CAR T therapy has revolutionized blood cancer treatment, but solid tumors have proven to be an obstacle. This work suggests that the obstacle may have an opening.
The key could be NFIL3, the door could be CRISPR, but only time will tell as the researchers continue their work.
Related Stories
Columbia University Team Identifies Key Cellular Switch Behind CAR T Cell Exhaustion FDA Probes Solid Tumors With New CAR T-Cell Delivery Montreal researchers discover SLAMF6 molecule directly shuts down immune cell defenses #ResearchersIdentifyNFIL3 #KeyDriver #CAR #CellExhaustion #Cancer #News
